3D Cell-Based Assays for Drug Screens: Challenges in Imaging, Image Analysis, and High-Content Analysis
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
The introduction of more relevant cell models in early preclinical drug discovery, combined with high-content imaging and automated analysis, is expected to increase the quality of compounds progressing to preclinical stages in the drug development pipeline. In this review we discuss the current switch to more relevant 3D cell culture models and associated challenges for high-throughput screening and high-content analysis. We propose that overcoming these challenges will enable front-loading the drug discovery pipeline with better biology, extracting the most from that biology, and, in general, improving translation between in vitro and in vivo models. This is expected to reduce the proportion of compounds that fail in vivo testing due to a lack of efficacy or to toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIH Image to ImageJ: 25 years of image analysis
Schneider, C. A., Rasband, W. S., & Eliceiri, K. W. (2012) · Nature Methods · doi:10.1038/nmeth.2089 · Cited by 64,638
Modeling Development and Disease with Organoids
Clevers, H. (2016) · Cell · doi:10.1016/j.cell.2016.05.082 · Cited by 3,196
Hydrogels as extracellular matrix mimics for 3D cell culture
Tibbitt, M. W., & Anseth, K. S. (2009) · Biotechnology and Bioengineering · doi:10.1002/bit.22361 · Cited by 2,727
Edmondson, R., Broglie, J. J., Adcock, A. F., & Yang, L. (2014) · ASSAY and Drug Development Technologies · doi:10.1089/adt.2014.573 · Cited by 2,515
Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients
van de Wetering, M., Francies, H. E., Francis, J. M., Bounova, G., Iorio, F., Pronk, A., van Houdt, W., van Gorp, J., Taylor-Weiner, A., Kester, L., et al. (2015) · Cell · doi:10.1016/j.cell.2015.03.053 · Cited by 2,408 · cited 1×
“While expansion of these tissue cultures is demanding compared with standard cell lines, they can still be used for compound screening.(70,71) Factors that may limit the scale at which PDX tumor material can be used in a screening context are the in vivo tissue propagation, the in vitro growth rate, which differs betw…”
BackgroundDisease-Specific Induced Pluripotent Stem Cells.
Park, I.-H., Arora, N., Huo, H., Maherali, N., Ahfeldt, T., Shimamura, A., Lensch, M. W., Cowan, C., Hochedlinger, K., & Daley, G. Q. (2008) · Cell · doi:10.1016/j.cell.2008.07.041 · Cited by 2,196 · cited 1×
“As a result, iPSC-derived tissues have been used to model a variety of different diseases, 56 such as cardiovascular, neurological, 57 and hepatic 58 disorders.”
MethodPatient-derived organoids model treatment response of metastatic gastrointestinal cancers
Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernández-Mateos, J., Khan, K., Lampis, A., Eason, K., Huntingford, I., Burke, R., et al. (2018) · Science · doi:10.1126/science.aao2774 · Cited by 2,096 · cited 1×
“53 The tumor material can be genetically characterized and the observed therapeutic response can lead to highly personalized treatment suggestions.”
BackgroundA living biobank of breast cancer organoids captures disease heterogeneity
Sachs, N., de Ligt, J., Kopper, O., Gogola, E., Bounova, G., Weeber, F., Balgobind, A. V., Wind, K., Gracanin, A., Begthel, H., et al. (2018) · Cell · doi:10.1016/j.cell.2017.11.010 · Cited by 1,973 · cited 1×
“70,71 Factors that may limit the scale at which PDX tumor material can be used in a screening context are the in vivo tissue propagation, the in vitro growth rate, which differs between types of tissue, and the high costs of required cell culture media and growth factors.”
BackgroundHow were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
Drost, J., & Clevers, H. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0007-6 · Cited by 1,790 · cited 1×
“15,16,68,69 While expansion of these tissue cultures is demanding compared with standard cell lines, they can still be used for compound screening.”
BackgroundDeconstructing the third dimension – how 3D culture microenvironments alter cellular cues
Baker, B. M., & Chen, C. S. (2012) · Journal of Cell Science · doi:10.1242/jcs.079509 · Cited by 1,760
Modeling Tissue Morphogenesis and Cancer in 3D
Yamada, K. M., & Cukierman, E. (2007) · Cell · doi:10.1016/j.cell.2007.08.006 · Cited by 1,751
Kidney organoids from human iPS cells contain multiple lineages and model human nephrogenesis
Takasato, M., Er, P. X., Chiu, H. S., Maier, B., Baillie, G. J., Ferguson, C., Parton, R. G., Wolvetang, E. J., Roost, M. S., Chuva de Sousa Lopes, S. M., et al. (2015) · Nature · doi:10.1038/nature15695 · Cited by 1,627 · cited 1×
“15,16,68,69 While expansion of these tissue cultures is demanding compared with standard cell lines, they can still be used for compound screening.”
BackgroundThree-dimensional in vitro cell culture models in drug discovery and drug repositioning
Langhans, S. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00006 · Cited by 1,522
Basement membrane complexes with biological activity
Kleinman, H. K., McGarvey, M. L., Hassell, J. R., Star, V. L., Cannon, F. B., Laurie, G. W., & Martin, G. R. (1986) · Biochemistry · doi:10.1021/bi00350a005 · Cited by 1,502 · cited 1×
“81 Synthetic hydrogels, in contrast, are well defined and can be readily modified and manufactured, thereby overcoming many problems associated with natural hydrogels.”
BackgroundDesigner matrices for intestinal stem cell and organoid culture
Gjorevski, N., Sachs, N., Manfrin, A., Giger, S., Bragina, M. E., Ordóñez-Morán, P., Clevers, H., & Lutolf, M. P. (2016) · Nature · doi:10.1038/nature20168 · Cited by 1,426
Three-dimensional culture models of normal and malignant breast epithelial cells
Lee, G. Y., Kenny, P. A., Lee, E. H., & Bissell, M. J. (2007) · Nature Methods · doi:10.1038/nmeth1015 · Cited by 1,336
In situ-forming hydrogels--review of temperature-sensitive systems
Ruel-Gariépy, E., & Leroux, J.-C. (2004) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2004.03.019 · Cited by 1,297
Kelm, J. M., Timmins, N. E., Brown, C. J., Fussenegger, M., & Nielsen, L. K. (2003) · Biotechnology and Bioengineering · doi:10.1002/bit.10655 · Cited by 934
Three-Dimensional Cell Cultures in Drug Discovery and Development
Fang, Y., & Eglen, R. M. (2017) · SLAS Discovery · doi:10.1177/1087057117696795 · Cited by 849
The use of 3-d cultures for high-throughput screening: the multicellular spheroid model.
Kunz-Schughart, L. A., Freyer, J. P., Hofstaedter, F., & Ebner, R. (2004) · SLAS DISCOVERY · doi:10.1177/1087057104265040 · Cited by 797
Organoids: A historical perspective of thinking in three dimensions
Simian, M., & Bissell, M. J. (2017) · Journal of Cell Biology · doi:10.1083/jcb.201610056 · Cited by 620
Screening out irrelevant cell-based models of disease
Horvath, P., Aulner, N., Bickle, M., Davies, A. M., Nery, E. D., Ebner, D., Montoya, M. C., Östling, P., Pietiäinen, V., Price, L. S., et al. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.175 · Cited by 525 · cited 1×
“91–95 While currently used extensively for 2D-cultured cells, high-content screening of 3D cell-based assays presents challenges for imaging, image analysis, computation, and data storage, as well as data visualization.”
Self-citationDefined three-dimensional microenvironments boost induction of pluripotency
Caiazzo, M., Okawa, Y., Ranga, A., Piersigilli, A., Tabata, Y., & Lutolf, M. P. (2016) · Nature Materials · doi:10.1038/nmat4536 · Cited by 271 · cited 1×
“61 Interestingly, because 3D culturing of iPSC-derived tissues is known to facilitate rapid reprogramming, 62 growing iPSC-derived tissues in 3D assays may overcome at least some of these hurdles.”
BackgroundAlzheimer's in 3D culture: Challenges and perspectives
D'Avanzo, C., Aronson, J., Kim, Y. H., Choi, S. H., Tanzi, R. E., & Kim, D. Y. (2015) · BioEssays · doi:10.1002/bies.201500063 · Cited by 111
Reconstruction of renal glomerular tissue using collagen vitrigel scaffold
Wang, P.-C., & Takezawa, T. (2005) · Journal of Bioscience and Bioengineering · doi:10.1263/jbb.99.529 · Cited by 59 · cited 1×
“43–45 However, co-culture systems also introduce an increased level of complexity to the culture system, which can be undesirable for high-throughput screens.”
Background
Cited by
Is it time to start transitioning from 2D to 3D cell culture?
Jensen, C., & Teng, Y. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00033 · Cited by 1,640
“Fluorescence microscopy is often still challenging in 3D cell cultures because unlike 2D cell culture where only a single xy image is taken, 3D cell cultures must obtain a z stack by taking a series of xy images at fixed intervals in the vertical direction by automated microscopes (Booij et al., 2019).”
BackgroundInfluentialScaffold-based 3D cell culture models in cancer research
Abuwatfa, W. H., Pitt, W. G., & Husseini, G. A. (2024) · Journal of Biomedical Science · doi:10.1186/s12929-024-00994-y · Cited by 324
Barbosa, M. A. G., Xavier, C. P. R., Pereira, R. F., Petrikaitė, V., & Vasconcelos, M. H. (2021) · Cancers · doi:10.3390/cancers14010190 · Cited by 285
“Concerning the wide-field fluorescence microscopy, the imaging capture time is improved compared with confocal imaging, but it requires post-imaging deconvolution in order to reduce out-of-focus fluorescence signal from nearby cells that interferes with the precision of the measurements [98,115].”
BackgroundMethodInfluentialApplication of LDH assay for therapeutic efficacy evaluation of ex vivo tumor models
Cox, M. C., Mendes, R., Silva, F., Mendes, T. F., Zelaya-Lazo, A., Halwachs, K., Purkal, J. J., Isidro, I. A., Félix, A., Boghaert, E. R., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-97894-0 · Cited by 58
deepOrganoid: a brightfield cell viability model for screening matrix-embedded organoids
Powell, R. T., Moussalli, M. J., Guo, L., Bae, G., Singh, P., Stephan, C., Shureiqi, I., & Davies, P. J. (2022) · SLAS Discovery · doi:10.1016/j.slasd.2022.03.004 · Cited by 37
Metadata
- Authors
- Booij, T. H., Price, L. S., & Danen, E. H. J.
- Venue
- SLAS Discovery
- Publisher
- Elsevier BV
- Published
- 2019-07
- Volume
- 24
- Issue
- 6
- Pages
- 615-627
- ISSN
- 2472-5552 (ISSN-L)
- OpenAlex
- W2918747683
- Cited by
- 176
- References
- 26
- FWCI
- 9.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.